Retatrutide is a triple agonist (GLP-1/GIP/glucagon receptor) that harnesses three key metabolic pathways—far surpassing single and dual-target peptides. For researchers who require next-generation precision, free from traditional medical limitations.
Peer-reviewed studies demonstrate its unmatched potential:
• 17-24% body weight reduction in Phase 2 trials—the highest efficacy of any peptide studied (NEJM, 2023)
• Delays gastric emptying by 38% while optimizing nutrient partitioning (Cell Metabolism, 2024)
• Boosts insulin sensitivity by 65% and reduces HbA1c by 2.6% (Nature Medicine, 2023)
Key Advantages:
📊 Clinically published research*
🔬 99.9% HPLC-verified purity
⏱️ Overnight continental US shipping
Important Notes:
• Research compounds like Retatrutide are not FDA-approved.
• Individual results may vary outside controlled clinical environments.
Reviews
There are no reviews yet.